Repare Therapeutics announced the first patient has been dosed in the company’s Phase 1 POLAR clinical trial evaluating RP-3467 alone and in combination with the poly-ADP ribose polymerase inhibitor, olaparib. RP-3467 is Repare’s fourth clinical program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX:
- Repare Therapeutics reports ‘encouraging’ Phase 1 camonsertib combo data
- Repare: Endometrial cancers with CCNE1 amplifications carry poor prognosis
- Repare Therapeutics Announces Strategic R&D Focus and Workforce Reduction
- Repare announces strategic reprioritization, to lay off 25% of workforce
- Repare to provide updated camonsertib data in Q4, says LifeSci Capital